<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00483899</url>
  </required_header>
  <id_info>
    <org_study_id>SIG102335</org_study_id>
    <nct_id>NCT00483899</nct_id>
  </id_info>
  <brief_title>Examine the Effect of Repeat Inhaled Doses of GW870086X on Lung Function in Mild Asthmatic Male Subjects</brief_title>
  <official_title>Double-blind, Placebo-controlled, 3-way Crossover Study to Investigate the Effect of 7-days Repeat Once Daily Inhaled Doses of GW870086X Administered Via DISKHALER on Airway Responsiveness to AMP in Mild Steroid-naive Male Asthmatics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to look at safety aspects and effects of repeat inhaled doses of
      GW870086X in mild asthmatics to develop this drug for its use in asthma and chronic
      obstructive pulmonary disease (COPD)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 7, 2005</start_date>
  <completion_date type="Actual">December 15, 2006</completion_date>
  <primary_completion_date type="Actual">December 15, 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in lung function 2 hours after treatment on day 7</measure>
    <time_frame>on day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in lung function 14 and 26 hours after treatment on day 7; Change in lung function 2 hours after treatment on day 1; Effects on blood and urine tests; effects on the heart, pulse rate and blood pressure; effects on the lungs</measure>
    <time_frame>2 hours after treatment on day 1, 14 and 26 hours after treatment on day 7;</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in Cohort 1 will be randomized to receive 0.5, 2 and 6 mg GW870086X and placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in Cohort 2 will be randomized to receive 3 mg GW870086X or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive 1 and 3 mg of GW870086X or placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW870086X</intervention_name>
    <description>Subjects will inhale 0.25 or 1.5 mg/inhalation GW870086X for four times</description>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_label>Cohort 1: Part A</arm_group_label>
    <arm_group_label>Cohort 2: Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching GW870086X will be administered by subjects</description>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_label>Cohort 1: Part A</arm_group_label>
    <arm_group_label>Cohort 2: Part A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male subjects aged 18-55

          -  Documented history of bronchial asthma diagnosed at least 6 months ago.

          -  Only being treated with short-acting beta-2-agonist therapy e.g. Ventolin

          -  Documented sensitivity to adenosine mono phosphate (AMP) at screening visit

          -  Demonstrate repeatable and reproducable response to inhaled AMP at the run-in visit

        Exclusion criteria:

          -  Any significant illness or disease

          -  History of life threatening asthma

          -  History of respiratory tract infection

          -  Subjects who take medication for their asthma, or other conditions, not compatible
             with this study.

          -  Smoker

          -  Subjects who are oversensitive to corticosteroids

          -  History of drug or alcohol abuse

          -  Donated blood within last 3 months

          -  Been involved in another clinical trial during the last 3 months

          -  Subjects who work night shifts

          -  Subjects who are undergoing de-sensitisation therapy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Lancashire</state>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE5 8AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/SIG102335?search=study&amp;search_terms=SIG102335#rs</url>
    <description>Results for study SIG102335 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2007</study_first_submitted>
  <study_first_submitted_qc>June 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2007</study_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GW870086X Asthma Crossover repeat dose inhaled</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

